| Study title | Dietary flaxseed: what we know and don't know about its effects on cardiovascular disease |
|---|---|
| Publication year | 2019 |
| Authors | Parikh M, Pierce GN |
| DOI | 10.1139/cjpp-2018-0485 |
| PubMed ID | 30562057 |
| Study design |
|
| Number of participants | |
| Population | Evidence from human clinical trials and experimental studies |
| Intervention | Dietary flaxseed |
| Comparator | Not applicable |
| Duration | Not applicable |
| Health claim | Flaxseed lowers LDL cholesterol and improves cardiovascular risk factors |
| Outcome measured | LDL cholesterol, blood pressure, atherosclerosis, cardiovascular outcomes |
| Main result | The review concludes that the strongest human evidence supports modest reductions in LDL cholesterol and blood pressure with regular flaxseed consumption. Evidence for preventing cardiovascular events remains insufficient. |
| Risk of bias | Moderate (narrative review) |
| Funding | University of Manitoba / Canadian research funding |
| Citation | Parikh M, Pierce GN. Dietary flaxseed: what we know and don't know about its effects on cardiovascular disease. Can J Physiol Pharmacol. 2019;97(2):75-84. doi:10.1139/cjpp-2018-0485. |